Immunogenicity and safety of an adjuvanted inactivated polio vaccine, IPV-Al, compared to standard IPV: A phase 3 observer-blinded, randomised, controlled trial in infants vaccinated at 6, 10, 14 weeks and 9 months of age

BACKGROUND: A dose-sparing inactivated polio vaccine (IPV-Al), obtained by adsorption of inactivated virus to an aluminium hydroxide adjuvant, can help mitigate global supply and the cost constraints of IPV. The objective of this trial was to demonstrate the non-inferiority of IPV-Al to standard IPV...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Vaccine
Main Authors: Bravo, Lulu C., Carlos, Josefina C., Gatchalian, Salvacion R., Montellano, May Emmeline B., Tabora, Charissa Fay Corazon B., Thierry-Carstensen, Birgit, Tingskov, Pernille Nyholm, Sørensen, Charlotte, Wachmann, Henrik, Bandyopadhyay, Ananda S., Nielsen, Pernille Ingemann, Kusk, Mie Vestergaard
Formato: Artigo
Idioma:Inglês
Publicado em: Elsevier Science 2020
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6983932/
https://ncbi.nlm.nih.gov/pubmed/31703934
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.vaccine.2019.10.064
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados